Oslo (Norway) and Niel (Belgium), 8 December 2016 - PCI Biotech (PCIB.OL), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.

The partnership is governed by a preclinical research collaboration agreement. In brief, the collaborators will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.

Please see attached press release for further details.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. PCI Biotech and eTheRNA immunotherapies

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via GlobeNewswire
HUG#2062990